Arcus Biosciences To Present Data From Ongoing EDGE-Gastric Study At ASCO Plenary And To Report Q3 Financial Results On November 7
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences (NYSE:RCUS) will present data from the ongoing Phase 2 EDGE-Gastric study at the ASCO Monthly Plenary Series on November 7, 2023. The study evaluates the combination of domvanalimab and zimberelimab in patients with advanced gastrointestinal cancers. Arcus will also report its Q3 2023 financial results and host a conference call on the same day.
October 17, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences' presentation of the EDGE-Gastric study data and Q3 2023 financial results could impact its stock price.
The presentation of the EDGE-Gastric study data could potentially influence investors' perception of Arcus Biosciences' product pipeline, which could impact its stock price. Additionally, the company's Q3 2023 financial results could also influence its stock price depending on whether the results meet, exceed, or fall short of market expectations.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100